Velinotamig Drives Complete Renal Responses in Refractory SLE; 8 of 9 Patients Improve
CGEM sits 71% above its 52-week low of $6.732.
Summary
Cullinan's BCMAxCD3 T cell engager velinotamig produced clinically meaningful disease-activity reductions in 8 of 9 evaluable refractory SLE patients, with 4 of 7 proteinuric patients hitting complete renal response within 24 weeks. Safety held up: no dose-limiting toxicities, no ICANS, and no Grade 3 or higher CRS, with the two CRS events limited to Grade 1/2. This is the ACR Convergence readout Cullinan flagged in its September 24 data-calendar announcement, and it lands as the first clinical validation of the autoimmune T cell engager thesis beyond the oncology franchise. The company's lead asset remains zipalertinib, whose NDA submission started October 1 under the RTOR pathway, so velinotamig is upside optionality rather than the base case. Data are early — 12 patients treated, 9 evaluable, interim cutoff September 8 — and the program is licensed ex-Greater China from Genrix Bio, with a separate subcutaneous Phase 1b/2a running in ITP and warm AIHA.
At the time of this announcement, CGEM was trading at $11.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $727.9M. The 52-week trading range was $6.73 to $23.19. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.